Study objective-To provide an international perspective on the impact of congenital anomalies on infant mortality from 1950 to 1994. Design-Population-based study based on data obtained from vital statistics reported to the World Health Organisation. Settings-36 countries from Europe, the Middle East, the Americas, Asia, and the South Pacific. Results-On average, infant mortality declined 68.8 per cent from 1950 to 1994. In the countries studied, infant mortality attributable to congenital anomalies decreased by 33.4 per cent, although it recently increased in some countries in Central and Latin America and in Eastern Europe. Anomalies of the heart and of the central nervous system accounted for 48.9 per cent of infant deaths attributable to congenital anomalies. During 1990-1994, infant mortality attributable to congenital anomalies was inversely correlated to the per capita gross domestic product in the countries studied. At the same time, the proportion of infant deaths attributable to congenital malformations was directly correlated with the per capita gross domestic product. Conclusions-Congenital malformations account for an increasing proportion of infant deaths in both developed and developing countries. Infant mortality attributable to congenital anomalies is higher in poorer countries although as a proportion of infant deaths it is greater in wealthier countries. Conditions such as spina bifida, whose occurrence can be reduced through preventive strategies, still cause many infant deaths. The apparent increase of infant mortality because of congenital anomalies in some countries should be investigated to confirm the finding, find the causes, and provide prevention opportunities.
1
The great majority of these deaths occurred during the first year of life, and thus tend to contribute mostly to infant mortality rate, which is defined as the number of deaths per 1000 live births between birth and exact age one year. 2 The impact of congenital anomalies on infant mortality depends on many factors, including the prevalence of congenital anomalies, the prevalence of other competing causes of death, the quality and availability of medical and surgical care, and the presence and eVectiveness of primary prevention policies. Prenatal diagnosis followed by termination of aVected pregnancies may also influence the reported impact of congenital anomalies at or after birth. Because of the many factors involved, infant mortality attributable to congenital anomalies can be expected to vary substantially among countries. In some developing countries, for instance, infant mortality remains very high (as high as 10 per cent in 1995). 1 In these countries, the leading causes of infant deaths are related to malnutrition and infectious diseases, with congenital anomalies often accounting for 5 per cent or less of the deaths, 1 although striking geographical variations have been observed. For example, in the 1980s in Latin America and the Caribbean, the proportion of infant deaths attributable to congenital anomalies varied from approximately 2 to 27 per cent and ranked among the five leading causes of infant deaths in that region. 3 In contrast, in developed countries, the proportion of infant deaths because of congenital malformations tends to be high and has been increasing, even as infant mortality attributable to congenital malformations has fallen. 4 For example, from 1960 to 1994 in the United States, birth defect specific infant mortality declined 53 per cent (from 36 to 17 per 10 000 live births), but congenital anomalies are still the leading cause of infant mortality in that country. 5 Consistent with these data on infant mortality are reports showing a decline in neonatal mortality attributable to congenital anomalies during the past five decades. 6 In 1994 in the United States, anomalies of the heart and central nervous system accounted for a substantial proportion of infants deaths (31 and 13 per cent, respectively). 5 As improvements in overall infant health promise decreases in deaths attributable to malnutrition and infectious diseases, the relative impact of congenital anomalies on infant mortality can be expected to increase in many parts of the world. However, few studies so far provide an international perspective on current trends. We used population-based data obtained from vital statistics reported from 1950 to 1994 to the World Health Organisation (WHO) to describe international variations and time trends of infant mortality attributable to congenital anomalies during this period.
Methods
We derived the data for this study from files compiled by WHO from vital statistics reported to WHO by individual countries. The electronic files are publicly available on the WHO web site (http://www.who.int/whosis/ cratic Republic of Germany, Hungary, Poland, Romania, the Russian Federation, and the former Yugoslavia); Asia (Japan); the Middle East (Israel); and the South Pacific (Australia, New Zealand). For countries, such as Germany, the Czech and Slovak Republics, and the former Yugoslav Republics that experienced major border changes during recent years, we used the national boundaries as they existed before 1989 to establish consistency with data from previous years.
An infant death was considered to be attributable to a congenital anomaly if the underlying cause of death included a code for a congenital anomaly. Codes for congenital anomalies were defined as those listed in the congenital anomalies section of the International Classification of Disease (ICD), revision six to nine (ICD-6, ICD-7, ICD-8, and ICD-9). Table 1 shows the correspondence among some WHO codes adopted with the ICD revisions. In the ICD-9 system, implemented in 1979, the WHO code B440 includes both spina bifida and hydrocephalus (ICD codes 741 and 742.3), whereas in ICD-6 through ICD-8 it included spina bifida alone. We computed infant mortality rates using as the denominator the yearly number of live births. The legal requirements for the reporting of fetal deaths and live births vary from country to country and even within countries. WHO recommends that, if possible, all fetuses and infants weighing at least 500 g at birth, whether alive or dead, should be included in the statistics. When information on birth weight is unavailable, the corresponding criteria for gestational age (22 completed weeks) or body length (25 cm crown to heel) should be used. The criteria for deciding whether an event has taken place within the perinatal period should be applied in the order: (1) birth weight, (2) gestational age, (3) crown to heel length. 7 We used the Spearman coeYcient 8 to test the correlation between infant mortality attributable to congenital anomalies and a country's per capita gross domestic product. 
Results

TRENDS IN INFANT MORTALITY ATTRIBUTABLE TO
CONGENITAL ANOMALIES, 1950 ANOMALIES, -1994 In the countries that we studied, total infant mortality decreased about 70 per cent from Because of the adoption of ICD-9 coding in 1979, we were able to assess the impact of specific congenital anomalies on infant mortality 
Heart defects Total
Infant mortality and congenital anomaliesfor the later part of the study period. Figure 1 summarises the findings for 1990-1994 by major geographical area. Central nervous system defects accounted for a relatively higher proportion of infant deaths in Latin America compared with other areas, whereas the proportion attributable to heart defects was highest in the South Pacific and Japan, and that attributable to anomalies of the digestive systems was highest in Western and Eastern Europe.
RELATION WITH PER CAPITA GROSS DOMESTIC
PRODUCT
Infant mortality attributable to congenital anomalies in the countries examined showed a strong inverse correlation with per capita gross domestic product (r = −0.8, p < 0.001) for the period 1990-1994 (fig 2) . Infant mortality attributable to congenital anomalies as a proportion of all infant deaths correlated directly with per capita gross domestic product (r = 0.5, p < 0.005).
INFANT MORTALITY ATTRIBUTABLE TO SPECIFIC CONGENITAL ANOMALIES
Data were available for cardiac defects since 1950, for spina bifida from 1950 to 1977, and for spina bifida plus hydrocephalus beginning in 1978. In the United States, Canada, Cuba, Australia, New Zealand, Israel, Japan, and Western Europe, infant mortality attributable to spina bifida declined throughout the study period (fig 3) , and in the period 1990-94 was below 2.5 per 10 000 live births in almost every country studied (table 3) . A similar pattern was found in Eastern Europe, with the exception of Poland and Romania. In these two countries, infant mortality attributable to spina bifida increased or fluctuated and was approximately three times higher than in the rest of Europe. In most Central and Latin American countries, rates were stable or ranged slightly upward, with the exception of Cuba, where spina bifida related infant mortality decreased. Infant mortality attributable to heart defects also decreased in Western countries and in Cuba, Israel, Australia, and New Zealand. In these countries, with the exception of Cuba, infant mortality attributable to heart defects in the period 1990-1994 was less than 10 per 10 000 live births, approximately half the average rate reported in the period 1950-54. In Latin America the rate was on average 15 per 10 000 and was stable. In most of Eastern Europe infant mortality attributable to cardiac defects was also stable, with the exception of Bulgaria and Romania, where rates were twice those reported in the rest of Europe. In Japan, rates were 9.5 per 10 000 in the period 1950-1954, increased to a peak of 12 per 10 000 in [1975] [1976] [1977] [1978] [1979] and then declined to 8 per 10 000 in 1990-94. The limitations of the study reflect the limitations of our data source, which was the database of vital statistics maintained by WHO that was based on reports from individual countries. Because we were able to study in some detail only 36 countries (mostly those in Europe, the Americas, Japan, and the South Pacific), we were unable to assess infant mortality attributable to congenital anomalies in many parts of the world that have a high birth rate and presumably significant infant health challenges. These areas include all of Africa, the Indian subcontinent, and most of Asia. Even for those countries that we were able to study, our analyses were restricted to the type of congenital anomalies that are included by WHO in its list of reportable malformations. A further limitation of our study was the potential for error and variability inherent in using vital statistics to classify causes of death. The terminology on death certificates or the application of coding rules for the International Classification of Disease may diVer across countries or even within the same country across the years, thus limiting comparability among countries and the study of time trends. Even the definition of infant mortality may be open to interpretation, in that very early deaths, particularly among very premature babies or babies with congenital anomalies could be misclassified as stillbirths or late abortions. 10 WHO data take into account only the primary cause of death, and deaths of infants with congenital malformations may be attributed to other factors even if the congenital malformation was indeed the underlying cause of death. For instance, a new neonatal death certificate was introduced in England and Wales in 1986 that allowed multiple causes of death to be reported. However, only the first recorded condition was reported to WHO. It is intriguing therefore that a large decline in anencephaly as a cause of death was observed at around that time. Finally, we were unable to evaluate the impact of prenatal diagnosis of congenital malformations and termination of aVected pregnancies. Selective termination of pregnancies aVected by congenital malformations would reduce the number of an aVected infant that are born and, if common enough, would result in a decline in infant mortality attributable to congenital anomalies. The interpretation of such a decline must take into account the notion that no case of disease has been actually prevented. Because of the relatively recent introduction of eVective methods of prenatal diagnosis, their impact would be most felt in the most recent period covered by our study.
The strengths of the study reflect the strengths of vital records as a source of mortality data. Vital records are one of the few established, longstanding systems in which systematically recorded data cover essentially the whole population, making these records useful resources for tracking population-wide mortality over long periods.
Our findings are consistent with the studies on perinatal mortality from hospital-based registries in Europe, the United States, and Canada. These studies showed a 65 to 80 per cent decline in total perinatal mortality during the past 50 years, whereas the proportion of perinatal deaths attributable to congenital anomalies increased by up to 30 per cent. 6 The reduction of perinatal mortality was in great part associated with progress in the medical and surgical management of some of the major causes of perinatal deaths, including haemolytic disease of the newborn, labour complications and birth injury, asphyxia, infections, and premature birth. 11 12 The decline in total infant mortality reported in our study probably reflects this progress. The slower decline in infant mortality attributable to congenital anomalies suggests that progress in the care of infants with congenital malformations has been less successful or less pervasive in the population. Because many structural anomalies require prompt and often complex medical and surgical care, it is not unexpected that progress seems to have been slower in countries that can devote less of their collective wealth to the care of infants with congenital malformations. Factors other than changes in survival also may have played a part in the observed trends of infant mortality attributable to congenital anomalies. As mentioned previously, selective termination of an aVected pregnancy is likely to have had an impact, particularly in the last two decades of the study and in countries where prenatal diagnosis is more prevalent and pregnancy termination is legal. This issue raises the question whether the lowest mortality attributable to congenital anomalies is unconditionally optimal. In the case of spina bifida, for example, the contrast is between, on the one hand, preventing disease by periconceptional folic acid use or improving survival among the aVected by optimal medical and surgical treatment, and, on the other hand, terminating aVected pregnancies. It is critical that public health professionals and policy makers recognise, assess, and monitor individually these three modes of action. Changes in ascertainment, diagnostic techniques, and reporting practices have the potential of increasing the apparent rate of congenital malformations. Nevertheless, the finding that in some countries in South America and in Eastern Europe infant mortality attributable to congenital anomalies is not decreasing or is actually increasing is of concern and should be investigated to assess the situation and to identify causes and prevention opportunities. Finally, the slower decline of infant mortality attributable to congenital anomalies compared with that attributable to other causes underscores the urgent need to find eVective means of primary prevention and to implement those that are known. Spina bifida, for example, caused more than 16 000 deaths in the countries studied in 1990-1994. That perhaps half or more of these deaths could have been prevented by maternal consumption of suYcient levels of folic acid 13 is a reminder of the continuing challenges facing medical professionals and public health oYcials in decreasing the burden of mortality attributable to congenital malformations worldwide.
